Safety Study to Test the Safety of HspE7 and Poly-ICLC Given in Patients With Cervical Intraepithelial Neoplasia

PHASE1UnknownINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions
Cervical Intraepithelial Neoplasia
Interventions
BIOLOGICAL

HspE7 and Poly-ICLC

3 injections of HspE7 and Poly ICLC given every 28 days for 3 injections

Trial Locations (8)

10461

Montefiore Medical Center, New York

30912

Medical College of Georgia, Augusta

73104

University of Oklahoma Health Sciences Center (OUHSC) / OU Medical Center, Oklahoma City

77030

Baylor College of Medicine, Houston

84062

Mt Timpanagos Women's Health Center, Pleasant Grove

84070

Salt Lake Women's Center, South Salt Lake

90033

University of Southern California, Los Angeles

92108

Medical Center for Clinical Research, San Diego

All Listed Sponsors
lead

Nventa Biopharmaceuticals Corporation

INDUSTRY